We have located links that may give you full text access.
Perioperative immune checkpoint blockades improve prognosis of resectable non-small cell lung cancer.
European Journal of Cardio-thoracic Surgery 2024 March 27
OBJECTIVES: Immune checkpoint blockades (ICB) have been proven to improve prognosis of non-small cell lung (NSCLC) in the neoadjuvant setting, while whether its perioperative use could bring extra benefit remained unidentified. We aimed to demonstrate the prognostic benefit of perioperative ICB over preoperative-only use and investigate who could benefit from this "sandwich ICB therapy".
METHODS: Patients undergoing neoadjuvant therapy followed by surgery from 2018 to 2022 was retrospectively reviewed, and were divided into four groups based on the perioperative regimens: pre-ICB + post-CT, pre-ICB-only, pre-CT + post-ICB, and pre-CT-only. Treatment-related adverse events, surgical outcomes, therapeutic response, recurrence-free survival (RFS) and overall survival (OS) were compared.
RESULTS: Of 214 enrolled patients with preoperative therapy, 108 underwent immunochemotherapy and 106 underwent platinum-based chemotherapy. Compared with preoperative chemotherapy, preoperative immunochemotherapy was demonstrated with significantly higher major pathologic response (MPR, 57/108 vs 12/106) and pathologic complete response (pCR, 35/108 vs 4/106) rates with comparable adverse events. Regarding survival, perioperative ICB significantly improved the RFS (vs pre-CT-only HR, 0.15; 95% CI, 0.09-0.27; vs pre-ICB-only HR, 0.36; 95% CI, 0.15-0.88) and OS (vs pre-CT-only HR, 0.24; 95% CI, 0.08-0.68). In patients without MPR, perioperative ICB was observed to decrease the risk of recurrence (HR, 0.31; 95% CI 0.11-0.83) compared with preoperative ICB, and was an independent prognostic factor (p < 0.05) for RFS.
CONCLUSIONS: Perioperative ICB showed promising efficacy in improving pathological response and survival outcomes of resectable NSCLC. For patients without MPR after resection followed by preoperative ICB, sequential ICB treatment could be considered.
METHODS: Patients undergoing neoadjuvant therapy followed by surgery from 2018 to 2022 was retrospectively reviewed, and were divided into four groups based on the perioperative regimens: pre-ICB + post-CT, pre-ICB-only, pre-CT + post-ICB, and pre-CT-only. Treatment-related adverse events, surgical outcomes, therapeutic response, recurrence-free survival (RFS) and overall survival (OS) were compared.
RESULTS: Of 214 enrolled patients with preoperative therapy, 108 underwent immunochemotherapy and 106 underwent platinum-based chemotherapy. Compared with preoperative chemotherapy, preoperative immunochemotherapy was demonstrated with significantly higher major pathologic response (MPR, 57/108 vs 12/106) and pathologic complete response (pCR, 35/108 vs 4/106) rates with comparable adverse events. Regarding survival, perioperative ICB significantly improved the RFS (vs pre-CT-only HR, 0.15; 95% CI, 0.09-0.27; vs pre-ICB-only HR, 0.36; 95% CI, 0.15-0.88) and OS (vs pre-CT-only HR, 0.24; 95% CI, 0.08-0.68). In patients without MPR, perioperative ICB was observed to decrease the risk of recurrence (HR, 0.31; 95% CI 0.11-0.83) compared with preoperative ICB, and was an independent prognostic factor (p < 0.05) for RFS.
CONCLUSIONS: Perioperative ICB showed promising efficacy in improving pathological response and survival outcomes of resectable NSCLC. For patients without MPR after resection followed by preoperative ICB, sequential ICB treatment could be considered.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app